Based on phase 3 trial findings, investigators conclude that transdermal estradiol should be a standard of care ADT option for patients with nonmetastatic prostate cancer. Transdermal estradiol (tE2) ...
The proportion of patients achieving a prostate-specific antigen nadir less than or equal to 0.2 ng/ml was exactly the same for patients treated with transdermal estradiol patches and those treated ...
Transdermal estradiol patches — the same ones used to curb menopause symptoms in women — are an effective alternative to luteinizing hormone–releasing hormone agonists to lower PSA levels in men with ...
Transdermal estradiol patches show similar PSA response to LHRHa when combined with ARPIs in metastatic prostate cancer. The STAMPEDE trial indicates tE2 patches offer a favorable safety profile, ...
CHARLESTON, S.C., June 30, 2025 /PRNewswire/ -- Afaxys, Inc., a Public Benefit Corporation and first-of-its kind socially conscious healthcare company focused on serving public health professionals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results